Gisela Borges

Gisela Borges

Auto-generated profile, based on publicly available information

Gisela Borges

Neuropsychopharmacology & Psychobiology Research Group, University of Cádiz, Cádiz, Spain; Departamento de Biologia Experimental, Centro de Investigação Médica da Faculdade de Medicina da Universidade do Porto (CIM-FMUP), Porto, Portugal; Instituto de Biologia Molecular e Celular (IBMC) e Instituto de Investigação e Inovação em Saúde (I3S), Universidade do Porto, Portugal

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2016 in Neuroscience
Verified
Journal Article
Closed access
MLMeritxell Llorca-Torralba
Meritxell Llorca-Torralba
GBGisela Borges
Gisela Borges
FNFani Neto
Fani Neto
JMJuan Antonio Mico
Juan Antonio Mico
EBEsther Berrocoso
Esther Berrocoso

1 December 2011 in Current Neuropharmacology
Verified
Journal Article
Open access
PDF file
FNFani Neto
Fani Neto
GBGisela Borges
Gisela Borges
Sonia Torres SánchezSonia Torres Sánchez
Sonia Torres Sánchez
JMJuan A. Mico
Juan A. Mico
EBEsther Berrocoso
Esther Berrocoso
Depression is a neuropsychiatric disorder affecting a huge percentage of the active population especially in developed countries. Research has devoted much of its attention to this problematic and many drugs have been developed and are currently prescribed to treat this pathology. Yet, many patients are refractory to the available therapeutic drugs, which mainly act by increasing the levels of the monoamines serotonin and noradrenaline in the synaptic cleft. Even in the cases antidepressants are effective, it is usually observed a delay of a few weeks between the onset of treatment and remission of the clinical symptoms. Additionally, many of these patients who show remission with antidepressant therapy present a relapse of depression upon treatment cessation. Thus research has focused on other possible molecular targets, besides monoamines, underlying depression. Both basic and clinical evidence indicates that depression is associated with several structural and neurochemical changes where the levels of neurotrophins, particularly of brain-derived neurotrophic factor (BDNF), are altered. Antidepressants, as well as other therapeutic strategies, seem to restore these levels. Neuronal atrophy, mostly detected in limbic structures that regulate mood and cognition, like the hippocampus, is observed in depressed patients and in animal behavioural paradigms for depression. Moreover, chronic antidepressant treatment enhances adult hippocampal neurogenesis, supporting the notion that this event underlies antidepressants effects. Here we review some of the preclinical and clinical studies, aimed at disclosing the role of neurotrophins in the pathophysiological mechanisms of depression and the mode of action of antidepressants, which favour the neurotrophic/neurogenic hypothesis.

29 October 2011 in Psychopharmacology
Verified
Journal Article
Closed access
PDF file
CACristina Alba-Delgado
Cristina Alba-Delgado
GBGisela Borges
Gisela Borges
PSPilar Sánchez-Blázquez
Pilar Sánchez-Blázquez
JOJorge E. Ortega
Jorge E. Ortega
IHIgor Horrillo
Igor Horrillo
EBEsther Berrocoso
Esther Berrocoso

1 June 2014 in Anesthesiology
Verified
Journal Article
Open access
PDF file
GBGisela Borges
Gisela Borges
FNFani Neto
Fani Neto
JMJuan Antonio Mico
Juan Antonio Mico
EBEsther Berrocoso
Esther Berrocoso
Background: Nonsteroidal anti-inflammatory drugs are effective for arthritic pain, but it is unknown whether they also benefit anxiety and depression that frequently coexist with pain. Using the monoarthritis model, the authors evaluated the activation of extracellular signal–regulated kinases 1 and 2 (ERK1/2) in structures implicated in both sensorial and emotional pain spheres, and it was verified whether analgesia can reverse monoarthritis-mediated affective responses. Methods: Monoarthritis was induced in male rats by complete Freund’s adjuvant injection. Allodynia (ankle-bend test), mechanical hyperalgesia (paw-pinch test), anxiety- and depression-like behaviors (elevated zero maze and forced swimming tests, respectively), and ERK1/2 phosphorylation (Western blot) in the spinal cord, paragigantocellularis nucleus, locus coeruleus, and prefrontal cortex were evaluated at 4, 14, and 28 days postinoculation (n = 6 per group). Changes in these parameters were evaluated after induction of analgesia by topical diclofenac (n = 5 to 6 per group). Results: Despite the pain hypersensitivity and inflammation throughout the testing period, chronic monoarthritis (28 days) also resulted in depressive- (control [mean ± SEM]: 38.3 ± 3.7 vs. monoarthritis: 51.3 ± 2.0; P < 0.05) and anxiogenic-like behaviors (control: 36.8 ± 3.7 vs. monoarthritis: 13.2 ± 2.9; P < 0.001). These changes coincided with increased ERK1/2 activation in the spinal cord, paragigantocellularis, locus coeruleus, and prefrontal cortex (control vs. monoarthritis: 1.0 ± 0.0 vs. 5.1 ± 20.8, P < 0.001; 0.9 ± 0.0 vs. 1.9 ± 0.4, P < 0.05; 1.0 ± 0.3 vs. 2.9 ± 0.6, P < 0.01; and 1.0 ± 0.0 vs. 1.8 ± 0.1, P < 0.05, respectively). Diclofenac decreased the pain threshold of the inflamed paw and reversed the anxio-depressive state, restoring ERK1/2 activation levels in the regions analyzed. Conclusion: Chronic monoarthritis induces affective disorders associated with ERK1/2 phosphorylation in paragigantocellularis, locus coeruleus, and prefrontal cortex which are reversed by diclofenac analgesia. (Anesthesiology 2014; 120:1476-90)

1 July 2015 in Progress in Neuro-Psychopharmacology and Biological Psychiatry
Verified
Journal Article
Closed access
GBGisela Borges
Gisela Borges
EBEsther Berrocoso
Esther Berrocoso
JMJuan Antonio Mico
Juan Antonio Mico
FNFani Neto
Fani Neto

1 February 2017 in International Journal of Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
GBGisela Borges
Gisela Borges
CMCristina Miguelez
Cristina Miguelez
FNFani Neto
Fani Neto
JMJuan Antonio Mico
Juan Antonio Mico
LULuisa Ugedo
Luisa Ugedo
EBEsther Berrocoso
Esther Berrocoso
There is increasing evidence suggesting that the Locus Coeruleus plays a role in pain-related anxiety. Indeed, we previously found that prolonged arthritis produces anxiety-like behavior in rats, along with enhanced expression of phosphorylated extracellular signal-regulated kinase 1/2 (a marker of plasticity) in the Locus Coeruleus. However, it is unknown how this effect correlates with the electrophysiological activity of Locus Coeruleus neurons or pain-related anxiety. Using the complete Freund’s adjuvant model of monoarthritis in male Sprague-Dawley rats, we studied the behavioral attributes of pain and anxiety as well as Locus Coeruleus electrophysiology in vivo 1 (MA1W) and 4 weeks (MA4W) after disease induction. The manifestation of anxiety in MA4W was accompanied by dampened tonic Locus Coeruleus activity, which was coupled to an exacerbated evoked Locus Coeruleus response to noxious stimulation of the inflamed and healthy paw. When a mitogen-activating extracellular kinase inhibitor was administered to the contralateral Locus Coeruleus of MA4W, the phosphorylated extracellular signal-regulated kinase 1/2 levels in the Locus Coeruleus were restored and the exaggerated evoked response was blocked, reversing the anxiogenic-like behavior while pain hypersensitivity remained unaltered. As phosphorylated extracellular signal-regulated kinase 1/2 blockade in the Locus Coeruleus relieved anxiety and counteracted altered LC function, we propose that phosphorylated extracellular signal-regulated kinase 1/2 activation in the Locus Coeruleus plays a crucial role in pain-related anxiety.